Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia
American Journal of Perinatology · 01.07.2026 · 43 (10) · 1335-1344
DOI: 10.1055/a-2753-9323 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift American Journal of Perinatology, erschienen am 01.07.2026. Verfasst von James Bussel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medical College, New York, New York, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunoglobulins, Intravenous, Prednisone, Thrombocytopenia, Neonatal Alloimmune. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study is sponsored by Johnson & Johnson.
Abstract (Originalsprache)
Nipocalimab, a neonatal Fc receptor blocker, showed evidence of efficacy and safety in preventing or delaying fetal anemia in a phase 2 study of early-onset severe hemolytic disease of the fetus and newborn, demonstrating potential for treatment of other maternal immunoglobulin G alloantibody-mediated fetal diseases. The phase 3 FREESIA-3 study aims to evaluate the efficacy and safety of nipocalimab or intravenous immunoglobulin (IVIG) with prednisone in pregnancies with a previous occurrence of fetal and neonatal alloimmune thrombocytopenia (FNAIT) with or without intracranial hemorrhage or severe fetal/neonatal bleeding (high- or standard-risk, respectively). FREESIA-3 is a phase 3, open-label, randomized, multicenter study in pregnant individuals at risk for FNAIT. Participants are randomized 4:1 to receive either weekly 45 mg/kg intravenous nipocalimab or weekly IVIG with prednisone starting at 13 to 18 weeks of gestational age (standard-risk) or 12 weeks of gestational age (high-risk) until delivery. During treatment, pregnant participants will receive ultrasound monitoring every 2 weeks for fetal bleeding, growth, and development. Postnatal follow-up is 24 weeks for maternal participants and 104 weeks for neonates/infants. The primary endpoint is an adverse outcome of death or adjudicated severe bleeding in utero up to 1 week postbirth, or platelet count at birth of < 30 × 109/L in a fetus/neonate. Secondary endpoints include fetal/neonatal death, neonatal platelet count at birth, nadir neonatal platelet count over 1 week postbirth, neonate requiring platelet transfusion(s), adjudicated fetal and neonatal bleeding up to 1 week postbirth, neonate receiving IVIG for thrombocytopenia, safety in maternal participants and neonates/infants, and immunogenicity of nipocalimab. Exploratory endpoints include patient- and caregiver-reported outcome assessments and nipocalimab pharmacokinetics and pharmacodynamics. FREESIA-3, an open-label, multicenter, randomized, phase 3 study, will evaluate the efficacy and safety of nipocalimab in both standard- and high-risk pregnancies for FNAIT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Hematology/Oncology, Weill Cornell Medical College, New York, New York, United States.
- New York Presbyterian Hospital, New York, New York, United States.
- Johnson & Johnson, Spring House, Pennsylvania, United States.
- Johnson & Johnson Biologics BV, Leiden, the Netherlands.
Förderung
- This study is sponsored by Johnson & Johnson
Zitieren
APA
Bussel, J., Stegmann, B., Baker, P., Oey, A., Jiang, Y., Zaha, R., Van Valkenburgh, H., & Keshinro, B. (2026). Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology, 43(10), 1335-1344. https://doi.org/10.1055/a-2753-9323
Vancouver
Bussel J, Stegmann B, Baker P, Oey A, Jiang Y, Zaha R, et al. Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia. American Journal of Perinatology. 2026;43(10):1335-1344. doi:10.1055/a-2753-9323
BibTeX
@article{Bussel2026,
author = {Bussel, James and Stegmann, Barbara and Baker, Pamela and Oey, Abbie and Jiang, Yanxin and Zaha, Rebecca and Van Valkenburgh, Hillary and Keshinro, Babajide},
title = {Design of a Phase 3, Multicenter, Randomized, Open-Label Study of Nipocalimab or IVIG and Prednisone in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia},
journal = {American Journal of Perinatology},
year = {2026},
volume = {43},
number = {10},
pages = {1335--1344},
doi = {10.1055/a-2753-9323}
}
EUVIMED